Licensing status

Publication and contact information

Cardiovascular disease

Ischemia/reperfusion injury

NADH dehydrogenase subunit 3 (ND3; MT-ND3)

In vitro and mouse studies suggest S-nitrosylation of
MT-ND3 could help prevent ischemia/reperfusion injury. In a mouse model for ischemia/reperfusion injury, injection of a mitochondria-selective S-nitrosylating agent (MitoSNO) during reperfusion decreased infarct size compared with injection of an untargeted S-nitrosylating compound.
In vitro, S-nitrosylation at cysteine 39 of MT-ND3 was required for the protective effect of MitoSNO and prevented reactive oxygen species production. Next steps include optimizing the MitoSNO formulation and conducting animal safety and Phase I studies.

SciBX 6(24); doi:10.1038/scibx.2013.600
Published online June 20, 2013

Patent issued in the EU; patent application filed in U.S.; available for licensing

Chouchani, E.T. et al. Nat. Med.; published online May 26, 2013;
Contact: Michael P. Murphy, Medical Research Council Mitochondrial Biology Unit, Cambridge, U.K.